Answers are grounded in this paper and cite their sources.
Podcast episode discusses challenges and solutions in identifying HER2-mutant lung cancer patients, emphasizing timely testing.
Episode 2 in our podcast series focuses on the critical challenge of identifying patients with HER2-mutant non-small cell lung cancer (NSCLC). We discuss why timely and comprehensive testing for HER2 mutations is vital for optimizing patient outcomes and how next-generation sequencing and molecular profiling are integrated into clinical practice. This episode covers the practical aspects and evolving standards of HER2 mutation testing, including the use of tumor and liquid biopsies, and addresses real-world barriers such as cost, access, and awareness. We also explore potential solutions, such as reflex testing and collaboration with molecular pathologists, to overcome current diagnostic challenges. This episode emphasizes the importance of accurate and early molecular diagnosis in ensuring patients receive the most effective, personalized therapies as the treatment landscape for HER2-mutant NSCLC continues to advance.
No takes yet. Share an insight, caveat, or question.
Subbiah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: